Politico puts GLP-1s in focus (with Scott)

APC CEO Scott Brunner's talked with Politico about a different angle on the GLP-1 story: personalization of those medications — how far it's gone since the FDA declared the shortages over, how far (maybe) it should go, and the murky road that further regulation might find itself walking down.

When it comes to so-called 'mass production' of personalized drugs...

Brunner [...] said “there’s room for a conversation” about whether the FDA should amend its guidance for compounded drugs — but he doesn’t know how regulators could implement changes without stepping on the practice of medicine.

“What does that look like? Where do you draw the line?” he said. “How much interference by a government agency in the medical judgment of a prescriber can you tolerate, can patients tolerate, can prescribers tolerate?”

And that's the critical point right there: Smart, careful regulation is one thing, but FDA shouldn't be squeezing itself between prescribers and patients.